Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (GB:0HI3)
LSE:0HI3
RESEARCH TOOLSreports
0HI3 Analyst Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0HI3 Stock 12 Month Forecast
Average Price Target
$42.22
▲(143.76% Upside)
| Highest Price Target$80.00 | Average Price Target$42.22 | Lowest Price Target$21.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
Reiterated
02/26/25
B.Riley Financial
Reiterated
02/14/25
Citi
Downgraded
02/12/25
H.C. Wainwright
Reiterated
02/12/25
Chardan Capital
Reiterated
02/11/25
Morgan Stanley
Reiterated
02/11/25
RBC Capital
Reiterated
02/11/25
Leerink Partners
Reiterated
02/11/25
Bank of America Securities
Reiterated
02/10/25
TD Cowen
Reiterated
02/10/25
Bernstein
$24
Hold
38.57%
Upside
Reiterated
11/27/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Sanofi (Other OTC: SNYNF)
Goldman Sachs
$28
Hold
61.66%
Upside
Reiterated
10/08/24
Goldman Sachs reiterates Neutral Rating on Arrowhead Pharma (ARWR)Goldman Sachs analyst Andrea Tan reiterated a Neutral rating and $28.00 price target on Arrowhead Pharma (NASDAQ: ARWR).
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
Reiterated
02/26/25
B.Riley Financial
Reiterated
02/14/25
Citi
Downgraded
02/12/25
H.C. Wainwright
Reiterated
02/12/25
Chardan Capital
Reiterated
02/11/25
Morgan Stanley
Reiterated
02/11/25
RBC Capital
Reiterated
02/11/25
Leerink Partners
Reiterated
02/11/25
Bank of America Securities
Reiterated
02/10/25
TD Cowen
Reiterated
02/10/25
Bernstein
$24
Hold
38.57%
Upside
Reiterated
11/27/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Sanofi (Other OTC: SNYNF)
Goldman Sachs
$28
Hold
61.66%
Upside
Reiterated
10/08/24
Goldman Sachs reiterates Neutral Rating on Arrowhead Pharma (ARWR)Goldman Sachs analyst Andrea Tan reiterated a Neutral rating and $28.00 price target on Arrowhead Pharma (NASDAQ: ARWR).
Best Analysts Covering Arrowhead Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy GB:0HI3 and Sell After:
1 Month
xxx
Success Rate
13/25 ratings generated profit
Average Return
-1.74%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 52.00% of your transactions generating a profit, with an average return of -1.74% per trade.
3 Months
xxx
Success Rate
21/40 ratings generated profit
Average Return
+8.13%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.50% of your transactions generating a profit, with an average return of +8.13% per trade.
1 Year
Success Rate
19/40 ratings generated profit
Average Return
+28.48%
reiterated a buy rating 28 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 47.50% of your transactions generating a profit, with an average return of +28.48% per trade.
2 Years
xxx
Success Rate
13/40 ratings generated profit
Average Return
+47.27%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 32.50% of your transactions generating a profit, with an average return of +47.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0HI3 Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
11
11
12
15
17
Buy
4
4
3
2
1
Hold
10
11
9
7
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
26
24
24
22
Each month's total comprises the sum of three months' worth of ratings.
0HI3 Financial Forecast
0HI3 Stock Forecast FAQ
What is GB:0HI3’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is $42.22.
What is GB:0HI3’s upside potential, based on the analysts’ average price target?
Arrowhead Pharmaceuticals has 143.76% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Arrowhead Pharmaceuticals a Buy, Sell or Hold?
Arrowhead Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals’s share price target?
The average share price target for Arrowhead Pharmaceuticals is $42.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $80.00 ,and the lowest forecast is $21.00. The average share price target represents 143.76% Increase from the current price of $17.32.
The highest analyst share price target is $80.00 ,and the lowest forecast is $21.00. The average share price target represents 143.76% Increase from the current price of $17.32.
What do analysts say about Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of Arrowhead Pharmaceuticals?
To buy shares of GB:0HI3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.